Discovery of potent and orally bioavailable heterocycle-based β3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 18, 2007, Pages 5245-5250

  Lafontaine, Jennifer A ^a   Day, Robert F ^a   Dibrino, Joe ^a   Hadcock, John R ^a   Hargrove, Diane M ^a   Linhares, Michael ^a   Martin, Kelly A ^a   Maurer, Tristan S ^a   Nardone, Nancy A ^a   Tess, David A ^a   DaSilva Jardine, Paul ^a  

^a PFIZER INC   (United States)

Author keywords

3 Adrenergic receptor agonists; Obesity; Thermogenesis

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; ADRENALIN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CP 331679; L 796568; NORADRENALIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENERGY EXPENDITURE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; RAT;

ADMINISTRATION, ORAL; ADRENERGIC BETA-AGONISTS; ANIMALS; BIOLOGICAL AVAILABILITY; OBESITY; RATS; RECEPTORS, ADRENERGIC, BETA-3;

RATTUS;

EID: 34547900257     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.06.072     Document Type: Article

References (24)

1. For a review of the topic:. Howe R. Drugs Fut. 18 (1993) 529
2. Tan S., and Curtis-Prior P.B. Int. J. Obes. 7 (1982) 409
3. Sher P.A., Mathur A., Fisher L.G., Wu G., Skwish S., Michel I.M., Seiler S.M., and Dickinson E.J. Bioorg. Med. Chem. Lett. 7 (1997) 1583
4. Arch J.R.S., Ainsworth A.T., Cawthorne M.A., Piercy V., Sennitt M.V., Thody V.E., Wilson C., and Wilson S. Nature 309 (1984) 163
5. Dow R.L. Exp. Opin. Invest. Drugs 6 (1997) 1811
6. 2 agonists reported in the literature, see Ref. 5. Weber A.E. Ann. Rep. Med. Chem. 33 (1998) 193
7. As described for: CP-331679 in Ref. 5 and for CL-316243 in. Sum F.W., Gilbert A., Venkatesan A.M., Lim K., Wong V., O'Dell M., Francisco G., Chen Z., Grosu G., Baker J., Ellingboe J., Malamas M., Gunawan I., Primeau J., Largis E., and Steiner K. Bioorg. Med. Chem. Lett. 9 (1999) 1921
8. Mathvink R.J., Tolman J.S., Chitty D., Candelore M.R., Cascieri M.A., Colwell L.F., Deng L., Feeney W.P., Forrest M.J., Hom G.J., MacIntyre D.E., Miller R.R., Stearns R.A., Tota L., Wyvratt M.J., Fisher M.H., and Weber A.E. J. Med. Chem. 43 (2000) 3832 and references cited therein
9. van Baak M.A., Hul G.B.J., Toubro S., Astrup A., Gottesdiener K.M., DeSmet M., and Saris W.H.M. Clin. Pharmacol. Ther. 76 (2002) 780
10. Stearns R.A., Miller R.R., Tang W., Kwei G.Y., Tang F.S., Mathvink R.J., Naylor E.M., Chitty D., Colandrea V.J., Weber A.E., Colleti A.E., Strauss J.R., Keohane C.A., Feeney W.P., Iliff S.A., and Chiu S.L. Drug Metab. Disp. 30 (2002) 771
11. Olah G.A. Friedel-Crafts and Related Reactions Vols. 1 and 2 (1963-1964), Wiley, New York
12. Kajigaeshi S., Kakinami T., Okamoto T., and Fujisaki S.. Bull. Chem. Soc. Jpn. 60 (1987) 1159
13. Lafontaine, J. A.; Morgan, B. P. PCT Int. Appl. WO 2003072572, 2003.
14. Dow, R. L.; Schneider, S. R. European Patent Application 1138685, 2001. (R)-Toluene-4-sulfonic acid 2-(6-chloropyridin-3-yl)-2-hydroxyethyl ester, described therein, was treated with 1 M NaOH in THF and water to afford epoxide 8 in 90% yield.
15. 50 < 100 nM and IA > 50% was tested at least twice in functional assays. Similar potencies and intrinsic activities were observed in the assays.
16. Mitsunobu O. Synthesis (1981) 1
17. Solubility measurements were made in pH 6.5 phosphate buffer.
18. Depocas F., and Hart J.S. J. Appl. Physiol. 10 (1957) 388
19. Animals were removed from general housing in the morning (7-7:30 am) and were deprived of food and water for the length of the oxygen consumption measurements. Animals were weighed (310-350 g), marked, and placed into individual activity-monitored chambers (17″ × 17″ × 5″). The system was calibrated and the run started (8:00-8:30 am). Oxygen consumption measurements were made every 10 min for 3 h, and then the animals were dosed with the test compound or vehicle. Oxygen consumption measurements were continued for 2 h. Oxygen consumption values associated with periods of high ambulatory activity (>100 counts/10 min) were excluded from all calculations, as were the first five values of the run and the first value after dosing.
20. b is the dissociation equilibrium constant for a competitive antagonist (the concentration which would occupy 50% of the receptors at equilibrium).
21. For the preparation of 28, see:. Ridge D.N., Hanifin J.W., Harten L.A., Johnson B.D., Menschik J., Nicolau G., Sloboda A.E., and Watts D.E. J. Med. Chem. 22 (1979) 1385
22. For a representative procedure, see:. Scott R.W., Neville S.N., Urbina A., Camp D., and Stankovic N. Org. Process Res. Dev. 10 (2006) 296
23. Compound 31 was prepared in two steps from ethanolamine, which was first protected as the benzyl carbamate, and then converted to the mesylate, under standard conditions.
24. As in:. Finley D.R., Bell M.G., Borel A.G., Bloomquist W.E., Cohen M.L., Heiman M.L., Kriauciunas A., Matthews D.P., Miles T., Neel D.A., Rito C.J., Sall D.J., Shuker A.J., Stephens T.W., Tinsley F.C., Winter M.A., and Jesudason C.D. Bioorg. Med. Chem. Lett. 16 (2006) 5691